Zogenix to Participate in the Global Mizuho Investor Conference 2017
November 29, 2017 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4
November 28, 2017 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
New Data from Zogenix’s Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at 71st American Epilepsy Society Annual Meeting
November 21, 2017 08:00 ET
|
Zogenix, Inc.
Updated Results of Phase 2 Study of ZX008 in Lennox Gastaut Syndrome to be Presented Data Demonstrating Disease Burden and Negative Impact on Quality of Life of Patients and Families Will Also be...
Zogenix to Present at Stifel 2017 Healthcare Conference
November 14, 2017 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results
November 07, 2017 16:01 ET
|
Zogenix, Inc.
During the third quarter, the Company announced positive top-line results from its Phase 3 Study 1 of ZX008 in patients with Dravet syndromeStudy 1 met primary endpoint of reduction in frequency of...
Zogenix to Release Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7
October 31, 2017 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds
October 19, 2017 02:00 ET
|
Zogenix, Inc.
Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results...
Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy
October 16, 2017 08:00 ET
|
Zogenix, Inc.
Findings Presented by Zogenix at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C. EMERYVILLE, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc....
Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 05, 2017 16:35 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Prices Public Offering of Common Stock
October 02, 2017 20:05 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...